ID   VU-SCC-147
AC   CVCL_L895
SY   93-VU-147T; 93VU-147T; 93VU147T; 147T
DR   cancercelllines; CVCL_L895
DR   Cosmic; 1122678
DR   Cosmic; 1530733
DR   Cosmic; 2296308
DR   GEO; GSM937834
DR   GEO; GSM937835
DR   Wikidata; Q54993383
RX   PubMed=7585617;
RX   PubMed=8824719;
RX   PubMed=17848307;
RX   PubMed=23419152;
RX   PubMed=23613873;
RX   PubMed=25275298;
RX   PubMed=26045983;
RX   PubMed=26122845;
RX   PubMed=28236344;
RX   PubMed=29156801;
RX   PubMed=31541927;
RX   PubMed=33802339;
CC   Part of: OPC-22 oral and pharyngeal cancer cell line panel.
CC   Doubling time: 2.2 days (PubMed=29156801).
CC   Karyotypic information: Has lost chromosome Y.
CC   Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Asp108Tyr (c.322G>T); Zygosity=Unspecified (PubMed=31541927; PubMed=33802339).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu257Arg (c.770T>G); ClinVar=VCV000142134; Zygosity=Unspecified (PubMed=23613873; PubMed=25275298; PubMed=31541927; PubMed=33802339).
CC   Transformant: NCBI_TaxID; 333760; Human papillomavirus type 16 (HPV16).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Genome sequenced (low read coverage).
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Misspelling: 93YU47; Cosmic=1530733.
CC   Derived from site: In situ; Oral cavity, floor of mouth; UBERON=UBERON_0003679.
ST   Source(s): PubMed=25275298; PubMed=29156801; PubMed=33802339
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 12
ST   D16S539: 9,11
ST   D18S51: 16
ST   D19S433: 14,15
ST   D21S11: 30,31 (PubMed=25275298)
ST   D21S11: 31 (PubMed=33802339)
ST   D2S1338: 20,24
ST   D3S1358: 15,17
ST   D5S818: 11,12
ST   D7S820: 10,11
ST   D8S1179: 13,15
ST   FGA: 22
ST   Penta D: 12,13.4
ST   Penta E: 11,12
ST   TH01: 7,9
ST   TPOX: 9,11
ST   vWA: 18
DI   NCIt; C4041; Floor of mouth squamous cell carcinoma
DI   ORDO; Orphanet_502363; Squamous cell carcinoma of the oral cavity
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 10-09-24; Version: 20
//
RX   PubMed=7585617;
RA   Steenbergen R.D.M., Hermsen M.A.J.A., Walboomers J.M.M., Joenje H.,
RA   Arwert F., Meijer C.J.L.M., Snijders P.J.F.;
RT   "Integrated human papillomavirus type 16 and loss of heterozygosity at
RT   11q22 and 18q21 in an oral carcinoma and its derivative cell line.";
RL   Cancer Res. 55:5465-5471(1995).
//
RX   PubMed=8824719; DOI=10.1002/(SICI)1098-2264(199601)15:1<1::AID-GCC1>3.0.CO;2-8;
RA   Hermsen M.A.J.A., Joenje H., Arwert F., Welters M.J.P., Braakhuis B.J.M.,
RA   Bagnay M., Westerveld A., Slater R.M.;
RT   "Centromeric breakage as a major cause of cytogenetic abnormalities in
RT   oral squamous cell carcinoma.";
RL   Genes Chromosomes Cancer 15:1-9(1996).
//
RX   PubMed=17848307; DOI=10.1016/j.ijrobp.2007.04.082;
RA   Yarbrough W.G., Whigham A., Brown B., Roach M., Slebos R.J.C.;
RT   "Phosphoinositide kinase-3 status associated with presence or absence
RT   of human papillomavirus in head and neck squamous cell carcinomas.";
RL   Int. J. Radiat. Oncol. Biol. Phys. 69:S98-S101(2007).
//
RX   PubMed=23419152; DOI=10.1186/gm419; PMCID=PMC3706778;
RA   Lechner M., Fenton T., West J., Wilson G., Feber A., Henderson S.,
RA   Thirlwell C., Dibra H.K., Jay A., Butcher L.M., Chakravarthy A.R.,
RA   Gratrix F., Patel N., Vaz F., O'Flynn P., Kalavrezos N.,
RA   Teschendorff A.E., Boshoff C., Beck S.;
RT   "Identification and functional validation of HPV-mediated
RT   hypermethylation in head and neck squamous cell carcinoma.";
RL   Genome Med. 5:15.1-15.16(2013).
//
RX   PubMed=23613873; DOI=10.1371/journal.pone.0061555; PMCID=PMC3629194;
RA   Martens-de Kemp S.R., Dalm S.U., Wijnolts F.M.J., Brink A.,
RA   Honeywell R.J., Peters G.J., Braakhuis B.J.M., Brakenhoff R.H.;
RT   "DNA-bound platinum is the major determinant of cisplatin sensitivity
RT   in head and neck squamous carcinoma cells.";
RL   PLoS ONE 8:E61555-E61555(2013).
//
RX   PubMed=25275298; DOI=10.18632/oncotarget.2417; PMCID=PMC4253406;
RA   Martin D., Abba M.C., Molinolo A.A., Vitale-Cross L., Wang Z.-Y.,
RA   Zaida M., Delic N.C., Samuels Y., Lyons J.G., Gutkind J.S.;
RT   "The head and neck cancer cell oncogenome: a platform for the
RT   development of precision molecular therapies.";
RL   Oncotarget 5:8906-8923(2014).
//
RX   PubMed=26045983; PMCID=PMC4449432;
RA   Ziemann F., Arenz A., Preising S., Wittekindt C., Klussmann J.P.,
RA   Engenhart-Cabillic R., Wittig A.;
RT   "Increased sensitivity of HPV-positive head and neck cancer cell lines
RT   to X-irradiation +/- cisplatin due to decreased expression of E6 and
RT   E7 oncoproteins and enhanced apoptosis.";
RL   Am. J. Cancer Res. 5:1017-1031(2015).
//
RX   PubMed=26122845; DOI=10.1158/0008-5472.CAN-15-0528;
RA   Stoepker C., Ameziane N., van der Lelij P., Kooi I.E., Oostra A.B.,
RA   Rooimans M.A., van Mil S.E., Brink A., Dietrich R., Balk J.A.,
RA   Ylstra B., Joenje H., Feller S.M., Brakenhoff R.H.;
RT   "Defects in the Fanconi anemia pathway and chromatid cohesion in head
RT   and neck cancer.";
RL   Cancer Res. 75:3543-3553(2015).
//
RX   PubMed=28236344; DOI=10.1002/hed.24729; PMCID=PMC5392184;
RA   Walline H.M., Goudsmit C.M., McHugh J.B., Tang A.L., Owen J.H.,
RA   Teh B.T., McKean E.L., Glover T.W., Graham M.P., Prince M.E.P.,
RA   Chepeha D.B., Chinn S.B., Ferris R.L., Gollin S.M., Hoffmann T.K.,
RA   Bier H., Brakenhoff R.H., Bradford C.R., Carey T.E.;
RG   University of Michigan Head and Neck Specialized Program of Research Excellence (SPORE) Program;
RT   "Integration of high-risk human papillomavirus into cellular
RT   cancer-related genes in head and neck cancer cell lines.";
RL   Head Neck 39:840-852(2017).
//
RX   PubMed=29156801; DOI=10.18632/oncotarget.21174; PMCID=PMC5689691;
RA   Kalu N.N., Mazumdar T., Peng S.-H., Shen L., Sambandam V., Rao X.-Y.,
RA   Xi Y.-X., Li L.-R., Qi Y., Gleber-Netto F.O., Patel A., Wang J.,
RA   Frederick M.J., Myers J.N., Pickering C.R., Johnson F.M.;
RT   "Genomic characterization of human papillomavirus-positive and
RT   -negative human squamous cell cancer cell lines.";
RL   Oncotarget 8:86369-86383(2017).
//
RX   PubMed=31541927; DOI=10.1016/j.oraloncology.2019.09.004; PMCID=PMC7372097;
RA   van Harten A.M., Poell J.B., Buijze M., Brink A., Wells S.I.,
RA   Leemans C.R., Wolthuis R.M.F., Brakenhoff R.H.;
RT   "Characterization of a head and neck cancer-derived cell line panel
RT   confirms the distinct TP53-proficient copy number-silent subclass.";
RL   Oral Oncol. 98:53-61(2019).
//
RX   PubMed=33802339; DOI=10.3390/cancers13051069; PMCID=PMC7959143;
RA   Gottgens E.-L., Ansems M., Leenders W.P.J., Bussink J., Span P.N.;
RT   "Genotyping and characterization of HPV status, hypoxia, and
RT   radiosensitivity in 22 head and neck cancer cell lines.";
RL   Cancers (Basel) 13:1069.1-1069.12(2021).
//